Evidence map›Paper›PMID 36350522›Full record

ArticleAdvances in experimental medicine and biology2022

DNA Labeling Using DNA Methyltransferases.

Miglė Tomkuvienė, Edita Kriukienė, Saulius Klimašauskas

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Miglė TomkuvienėInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Edita KriukienėInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Saulius KlimašauskasInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania. saulius.klimasauskas@bti.vu.lt.
Vilnius University · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA methyltransferases (MTases) uniquely combine the ability to recognize and covalently modify specific target sequences in DNA using the ubiquitous cofactor S-Adenosyl-L-methionine (AdoMet). Although DNA methylation plays important roles in biological signaling, the transferred methyl group is a poor reporter and is highly inert to further biocompatible derivatization. To unlock the biotechnological power of these enzymes, extended cofactor AdoMet analogs have been developed that enable targeted MTase-directed attachment of larger moieties containing functional or reporter groups onto DNA. As the enlarged cofactors are not always compatible with the active sites of native MTases, steric engineering of the active site has been employed to optimize their alkyltransferase activity. In addition to the described cofactor analogs, recently discovered atypical reactions of DNA cytosine-5 MTases involving non-cofactor-like compounds can also be exploited for targeted derivatization and labeling of DNA. Altogether, these approaches offer new powerful tools for sequence-specific covalent DNA labeling, leading to a variety of useful techniques in DNA research, diagnostics and nanotechnologies, and have already proven practical utility for optical DNA mapping and high-throughput epigenome studies.

Indexed as

DNA MethylationS-AdenosylmethionineDNADNA Modification MethylasesMethyltransferasesDNADNA Modification MethylasesMethyltransferasesS-AdenosylmethionineDNA methyltransferaseEnzyme engineeringEpigenomic mappingOptical mappingS-Adenosyl-L-methionineSynthetic cofactor AdoMet analogtargeted DNA labeling

Identifiers

PMID36350522
OpenAlexW4308773026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.